Erasca’s ERAS-0015 receives FDA Fast Track Designation for metastatic pancreatic adenocarcinoma following encouraging Phase 1 activity in KRAS G12X PDAC.
Written By: Shreya Desai, PharmD
Reviewed By: Pharmacally Editorial Team
Erasca, a clinical-stage precision oncology company focused on therapies for RAS/MAPK pathway-driven cancers, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ERAS-0015 for the treatment of patients with metastatic pancreatic adenocarcinoma.
ERAS-0015 is an investigational, oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling, with a potential best-in-class profile.
Fast Track Designation is intended to facilitate the development and expedite the review of therapies for serious conditions with unmet medical needs. Programs receiving the designation may benefit from more frequent interactions with the FDA and, if applicable criteria are met, may become eligible for accelerated approval, priority review, and rolling review.
Erasca said the designation, together with encouraging clinical activity and favorable tolerability observed to date, supports the continued development of ERAS-0015 in pancreatic and lung cancers.
Encouraging Phase 1 Clinical Activity
In July 2026, Erasca reported updated preliminary data from the AURORAS-1 Phase 1 trial (NCT06983743) in the United States, demonstrating encouraging clinical activity across RAS-mutant solid tumors.
In patients with second-line or later (2L+) KRAS G12X pancreatic ductal adenocarcinoma (PDAC), ERAS-0015 monotherapy produced a 57% overall response rate at eight weeks (uORR8wk) at the recommended dose for expansion (RDE) of 32 mg once daily.
According to Erasca, uORR8wk represents the overall response rate, including confirmed and unconfirmed responses, among patients who received their first dose of ERAS-0015 at least eight weeks before the May 25, 2026 data cutoff.
All responding patients across doses remained on treatment as of the data cutoff, and ERAS-0015 continued to demonstrate favorable tolerability.
ERAS-0015 Development Program
ERAS-0015 is being evaluated in the AURORAS-1 Phase 1 trial in patients with RAS-mutant solid tumors.
Early dose-escalation data demonstrated favorable safety and tolerability, linear pharmacokinetics, and confirmed and unconfirmed partial responses across multiple tumor types and RAS mutations. Confirmed partial responses were observed at doses as low as 8 mg once daily.
ERAS-0015 is also designed to help prevent resistance to mutant-selective inhibitors by inhibiting RAS wild-type variants. The compound has demonstrated favorable absorption, distribution, metabolism, and excretion (ADME) and pharmacokinetic properties in multiple animal species.
Future Clinical Development
Erasca has planned a Phase 3 trial in pancreatic cancer alongside two potentially registration-enabling trials in lung cancer.
Additional data from the monotherapy expansion and combination dose-escalation cohorts are expected in the first half of 2027, including data from the panitumumab combination.
ERAS-0015 remains investigational and has not been approved by the FDA.
Reference
About the Writer
Shreya Desai is a Doctor of Pharmacy professional with a strong academic record, having secured Rank 1 for three consecutive years, and a keen interest in clinical writing, clinical research, regulatory affairs, and pharmacovigilance.
With experience in medical communication and scientific writing, she brings strong research aptitude, scientific acumen, and effective communication skills to healthcare content development.
As a Pharmacally healthcare writer, Shreya focuses on creating clear, accurate, evidence-based medical content while translating complex scientific information into meaningful healthcare communication.